Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Janus Henderson's Global Life Sciences portfolio returned 12.10% in Q2 2026, outperforming its benchmark. Read the full analysis for more details.

On August 6, Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results showing royalty revenue up 32% year over year, just weeks after the company closed its acquisition of XOMA ...

Excited to Join Travere Therapeutics as Director, Scientific Engagement and Professional Societies / AbbVie Oncology, Asud Khaliq, cancer, Chris ...

VegFest Kelowna returns to City Park in downtown Kelowna on Sunday, Sept. 20. It brings together local businesses, food ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of ...

Mineralys is upgraded to Buy, with lorundrostat poised for FDA approval in December and a strong commercial launch ...

Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you ...

Complete Invesco Dorsey Wright Healthcare Momentum ETF funds overview by Barron's. View the PTH funds market news ...